Context Therapeutics Secures Full Economic Rights to CT-202 for $6.5M
CNTX has more than doubled off its 52-week low of $0.49.
Summary
Context Therapeutics amended its license agreement with BioAtla, paying $6.5 million to gain irrevocable, royalty-free, and fully paid-up rights to its key bispecific antibody, CT-202. This strategic move eliminates future milestone and royalty obligations, securing the long-term economics of the drug.
Key Events · M&A and Partnerships · CNTX
-
Amends License Agreement for CT-202
Context Therapeutics entered into a First Amendment to its license agreement with BioAtla, Inc., dated May 14, 2026, for exclusive rights to antibody assets, including CT-202.
-
Buys Out Future Milestones and Royalties
The company will pay BioAtla $4.5 million upfront and an additional $2.0 million by August 1, 2026, totaling $6.5 million, to eliminate all future milestone and royalty payments for CT-202.
-
Secures Irrevocable, Royalty-Free Rights
The amendment grants Context Therapeutics irrevocable, royalty-free, fully paid-up, and non-terminable exclusive licenses for CT-202 and other licensed antibodies, removing previous R&D and reporting obligations.
-
Strategic Investment in Key Pipeline Asset
This move provides Context with full economic rights to CT-202, a Nectin-4 x CD3 T cell engager that recently received FDA Fast Track Designation, allowing the company to capture potential long-term value.
Analysis · CNTX · Life Sciences
Context Therapeutics is making a significant strategic investment by buying out all future milestone and royalty obligations for its key drug candidate, CT-202, for a fixed payment of $6.5 million. This payment, while substantial at over 3% of the company's market cap, secures full economic rights to the asset, making the license irrevocable and royalty-free. This de-risks the long-term financial profile of CT-202, which recently received FDA Fast Track Designation, and removes ongoing reporting and development obligations to BioAtla. The company expects to initiate a Phase 1 trial for CT-202 in Q3 2026.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTX was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198.5M. The 52-week trading range was $0.49 to $3.62. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.